CClinicalTrials.gg
CompletedNCT07650162Updated Jun 17, 2026

The Effects of Beta-Alanine Supplementation on Mechanical Performance, Acid-Base Balance, Oxidative Stress, and Enzymatic Antioxidant Defence During Repeated Wingate Anaerobic Tests Under Normoxic and Hypoxic Conditions

An interventional study of beta-alanine and normoxic conditions in Cyclists and Healthy Adult Male, sponsored by The Jerzy Kukuczka Academy of Physical Education in Katowice. Completed at 1 site in Poland. Open to male participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by The Jerzy Kukuczka Academy of Physical Education in Katowice · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 6 years 6 months after the study started (first participant enrolled Nov 2019, registered Jun 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Male
01

Study summary

Beta-alanine is a dietary supplement that increases skeletal muscle carnosine concentration and may enhance the muscle's ability to buffer hydrogen ions produced during high-intensity exercise. This buffering effect could potentially delay fatigue and improve exercise performance, particularly under conditions that increase metabolic stress, such as hypoxia. However, previous studies examining the effects of beta-alanine supplementation on repeated sprint performance under hypoxic conditions have produced inconsistent findings.

The purpose of this study is to determine whether four weeks of beta-alanine supplementation improves repeated high-intensity cycling performance and influences markers of acid-base balance in trained male cyclists exercising under normoxic and hypoxic conditions. Participants will perform repeated Wingate anaerobic cycling tests before and after a four-week supplementation period with either beta-alanine or placebo.

Mechanical performance outcomes, including peak power, mean power, total work, and fatigue indices, will be assessed alongside physiological measures of metabolic stress, including blood lactate concentration, pH, bicarbonate concentration, and base excess. Performance and physiological responses will be compared between supplementation groups and environmental conditions.

The findings of this study may contribute to a better understanding of the ergogenic potential of beta-alanine supplementation during repeated high-intensity exercise and provide practical information for athletes and practitioners regarding the effectiveness of beta-alanine under conditions of reduced oxygen availability.

Read the detailed description

Beta-alanine is a non-essential amino acid and the rate-limiting precursor for the synthesis of carnosine, an intracellular dipeptide found in high concentrations within skeletal muscle. Carnosine contributes to intracellular acid-base regulation by buffering hydrogen ions (H+) produced during high-intensity exercise. Supplementation with beta-alanine has consistently been shown to increase muscle carnosine concentrations, potentially enhancing buffering capacity and delaying the onset of fatigue during exercise characterized by substantial glycolytic energy production.

The ergogenic potential of beta-alanine has been extensively investigated in a variety of exercise modalities. Previous studies and meta-analyses suggest that supplementation may improve performance during high-intensity exercise lasting approximately one to four minutes, where metabolic acidosis is considered an important contributor to fatigue. However, findings remain inconsistent, particularly in exercise protocols involving repeated maximal efforts and in environmental conditions that alter oxygen availability.

Exercise performed in hypoxic environments is associated with reduced oxygen delivery to working muscles, increased reliance on anaerobic glycolysis, accelerated accumulation of hydrogen ions and lactate, and greater disturbance of acid-base homeostasis. Consequently, hypoxic exercise may increase the physiological importance of buffering mechanisms and potentially enhance the relevance of interventions aimed at improving buffering capacity. Despite this theoretical rationale, limited information is available regarding the effectiveness of beta-alanine supplementation during repeated supramaximal exercise performed under hypoxic conditions.

The purpose of this study is to evaluate the effects of four weeks of beta-alanine supplementation on repeated high-intensity cycling performance and physiological responses associated with metabolic acidosis in trained male cyclists. The study utilizes a randomized, double-blind, placebo-controlled design. Participants complete repeated laboratory testing sessions under both normoxic and normobaric hypoxic conditions before and after the supplementation period.

Exercise performance is assessed using a repeated Wingate anaerobic cycling protocol consisting of three consecutive 30-second maximal efforts separated by standardized recovery intervals. The protocol was selected because it induces substantial anaerobic energy production and metabolic stress, allowing evaluation of both performance outcomes and buffering-related physiological responses. Testing is conducted under normoxic conditions and under normobaric hypoxia corresponding to an altitude of approximately 2500 meters above sea level.

Physiological measurements include assessments of blood lactate concentration and indicators of acid-base balance collected in conjunction with the exercise protocol. These measurements are intended to characterize the metabolic and buffering responses to repeated supramaximal exercise and to determine whether beta-alanine supplementation modifies these responses.

The study is designed to improve understanding of the role of beta-alanine supplementation in athletes performing repeated high-intensity exercise under conditions of normal and reduced oxygen availability. The findings may contribute to the evidence base regarding nutritional strategies intended to support performance during repeated maximal efforts and may help clarify whether environmental stressors such as hypoxia influence the ergogenic effectiveness of beta-alanine supplementation.

02

Conditions studied

  • Cyclists
  • Healthy Adult Male

Browse trials for

Keywords

  • muscle buffering
  • anaerobic performance
  • Wingate test
  • acid-base balance
  • hypoxia
  • cyclists
03

In context

Hypoxia

1,231 studies on the registry are indexed under Hypoxia; 241 are open to participants now.

This study's enrollment of 38 is below the median of 45 across 853 interventional studies indexed under Hypoxia.

Browse Hypoxia studies →

Lead sponsor

The Jerzy Kukuczka Academy of Physical Education in Katowice is the lead sponsor of 30 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy male participants aged 20-50 years
  • Regularly riding a bike (min. 5000 km on the bike in the last year)
  • Willingness to maintain habitual dietary and physical activity patterns throughout the study.
  • Willingness to refrain from consuming dietary supplements other than those provided as part of the study.

Exclusion criteria

Exclusion Criteria:

  • Prevalence of chronic diseases
  • β-alanine supplementation within the previous six months
  • Use of other dietary supplements, except carbohydrate and whey protein supplements
  • Adherence to a vegetarian or vegan diet
  • Participation in another clinical trial within the previous 3 months.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    BA-N

    Beta-alanine + normoxia

    Dietary Supplement: beta-alanine · Other: normoxic conditions

  • Placebo comparator
    PL-N

    Placebo + normoxia

    Other: normoxic conditions · Dietary Supplement: Placebo

  • Experimental
    BA-H

    Beta-alanine + hypoxia

    Dietary Supplement: beta-alanine · Other: Normobaric hypoxic conditions (≈2500 m)

  • Experimental
    PL-H

    Placebo + hypoxia

    Dietary Supplement: Placebo · Other: Normobaric hypoxic conditions (≈2500 m)

Interventions

  • Dietary supplementbeta-alanine

    β-alanine (6 g·day-¹)

    Also known as: BA

  • Othernormoxic conditions

    normoxic conditions

    Also known as: N

  • Dietary supplementPlacebo

    Placebo (6 g·day-¹)

  • OtherNormobaric hypoxic conditions (≈2500 m)

    Normobaric hypoxic conditions (≈2500 m)

    Also known as: H

06

What researchers measure

Primary outcomes

  1. Mean Power (W)

    Time frame: 4 weeks

Secondary outcomes

  1. Peak Power (W)

    Time frame: 4 weeks

  2. Relative Peak Power (W·kg-¹)

    Time frame: 4 weeks

  3. Total Work (J)

    Time frame: 4 weeks

  4. Fatigue Slope (W·s-¹)

    Time frame: 4 weeks

  5. Rate of Fatigue (%)

    Time frame: 4 weeks

  6. Time to Peak Power (s)

    Time frame: 4 weeks

  7. minimum power (MinP)

    Time frame: 4 weeks

  8. Lactate (mmol·L-¹)

    Time frame: 4 weeks

  9. pH

    Time frame: 4 weeks

  10. BE(B) (mmol·L-¹)

    Time frame: 4 weeks

  11. HCO₃- (mmol·L-¹)

    Time frame: 4 weeks

07

Study locations

1 site
  • Academy of Physical Education in Katowice
    Katowice, Poland
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised data will be available upon reasonable request.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07650162
Lead sponsor
The Jerzy Kukuczka Academy of Physical Education in Katowice
Responsible party
Mateusz Gawełczyk (Principal Investigator, The Jerzy Kukuczka Academy of Physical Education in Katowice) — Principal investigator
First posted
Jun 16, 2026
Start date
Nov 20, 2019
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026
Last update
Jun 17, 2026

Study contacts

Mateusz Gawelczyk, PhD
study director · Institute of Sport Sciences, Academy of Physical Education, 40-065 Katowice, Poland

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion